Status:
RECRUITING
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS
Lead Sponsor:
A.O.U. Città della Salute e della Scienza
Conditions:
Amyotrophic Lateral Sclerosis (ALS)
Eligibility:
All Genders
18+ years
Brief Summary
Amyotrophic Lateral Sclerosis (ALS) is a severe and incurable neurodegenerative disease of motor neurons with a dramatic socio-economic impact on the national health system. ALS is a complex disorder ...
Detailed Description
Specific aim 1 To perform an unbiased genetic screening and to measure biochemical and neuroradiological biomarkers in a deep-phenotyped cohort of ALS patients. In particular, the activities will be ...
Eligibility Criteria
Inclusion
- Diagnosis of ALS
Exclusion
- ALS patients under 18 years old
Key Trial Info
Start Date :
May 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 20 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06917924
Start Date
May 20 2023
End Date
November 20 2025
Last Update
April 9 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Istituto Auxologico Italiano
Milan, Italy, 20149
2
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Milan, Italy, 20156
3
Università degli Studi della Campania "Luigi Vanvitelli"
Napoli, Italy, 80138
4
AOU Citta della Salute e della Scienza di Torino
Torino, Italy, 10126